These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 23017815)
1. Time-dependent Cox regression: serial measurement of the cardiovascular biomarker proadrenomedullin improves survival prediction in patients with lower respiratory tract infection. Hartmann O; Schuetz P; Albrich WC; Anker SD; Mueller B; Schmidt T Int J Cardiol; 2012 Nov; 161(3):166-73. PubMed ID: 23017815 [TBL] [Abstract][Full Text] [Related]
2. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Maisel A; Mueller C; Nowak RM; Peacock WF; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng LL; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Hartmann O; Morgenthaler NG; Anker SD J Am Coll Cardiol; 2011 Aug; 58(10):1057-67. PubMed ID: 21867843 [TBL] [Abstract][Full Text] [Related]
3. Pro-Adrenomedullin predicts 10-year all-cause mortality in community-dwelling patients: a prospective cohort study. Odermatt J; Meili M; Hersberger L; Bolliger R; Christ-Crain M; Briel M; Bucher HC; Mueller B; Schuetz P BMC Cardiovasc Disord; 2017 Jul; 17(1):178. PubMed ID: 28676115 [TBL] [Abstract][Full Text] [Related]
4. Stress markers predict mortality in patients with nonspecific complaints presenting to the emergency department and may be a useful risk stratification tool to support disposition planning. Nickel CH; Messmer AS; Geigy N; Misch F; Mueller B; Dusemund F; Hertel S; Hartmann O; Giersdorf S; Bingisser R Acad Emerg Med; 2013 Jul; 20(7):670-9. PubMed ID: 23859580 [TBL] [Abstract][Full Text] [Related]
6. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure. Alehagen U; Dahlström U; Rehfeld JF; Goetze JP J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592 [TBL] [Abstract][Full Text] [Related]
7. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Maisel A; Mueller C; Nowak R; Peacock WF; Landsberg JW; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng L; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Terracciano G; Kremastinos D; Hartmann O; von Haehling S; Bergmann A; Morgenthaler NG; Anker SD J Am Coll Cardiol; 2010 May; 55(19):2062-76. PubMed ID: 20447528 [TBL] [Abstract][Full Text] [Related]
8. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Tzikas S; Keller T; Ojeda FM; Zeller T; Wild PS; Lubos E; Kunde J; Baldus S; Bickel C; Lackner KJ; Münzel TF; Blankenberg S Heart; 2013 Mar; 99(6):388-95. PubMed ID: 23213173 [TBL] [Abstract][Full Text] [Related]
9. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Christ-Crain M; Morgenthaler NG; Struck J; Harbarth S; Bergmann A; Müller B Crit Care; 2005; 9(6):R816-24. PubMed ID: 16356231 [TBL] [Abstract][Full Text] [Related]
10. Associations of mid-regional pro-adrenomedullin levels to cardiovascular and metabolic abnormalities, and mortality in an elderly population from the community. Eggers KM; Venge P; Lindahl B; Lind L Int J Cardiol; 2013 Oct; 168(4):3537-42. PubMed ID: 23722054 [TBL] [Abstract][Full Text] [Related]
11. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B Crit Care; 2006; 10(3):R96. PubMed ID: 16805922 [TBL] [Abstract][Full Text] [Related]
12. Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients. Haaf P; Twerenbold R; Reichlin T; Faoro J; Reiter M; Meune C; Steuer S; Bassetti S; Ziller R; Balmelli C; Campodarve I; Zellweger C; Kilchenmann A; Irfan A; Papassotiriou J; Drexler B; Mueller C Int J Cardiol; 2013 Sep; 168(2):1048-55. PubMed ID: 23199555 [TBL] [Abstract][Full Text] [Related]
13. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis. Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637 [TBL] [Abstract][Full Text] [Related]
14. Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial. Möckel M; Searle J; Hartmann O; Anker SD; Peacock WF; Wu AH; Maisel A; ; Slagman A; Vollert JO; Papassotiriou J; Anand I; Christenson R; Daniels LB; Filippatos GS; Hogan C; Morgenthaler N; Mueller C; Neath SX; Ng L; Nowak R; Richards M; Di Somma S; Ponikowski P Emerg Med J; 2013 Aug; 30(8):633-7. PubMed ID: 22962091 [TBL] [Abstract][Full Text] [Related]
15. Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population. Brouwers FP; de Boer RA; van der Harst P; Struck J; de Jong PE; de Zeeuw D; Gans RO; Gansevoort RT; Hillege HL; van Gilst WH; Bakker SJ Heart; 2012 Sep; 98(18):1348-53. PubMed ID: 22821276 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia. Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588 [TBL] [Abstract][Full Text] [Related]
17. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? Pereira JM; Azevedo A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA Rev Port Pneumol (2006); 2016; 22(6):308-314. PubMed ID: 27160747 [TBL] [Abstract][Full Text] [Related]
18. MR-pro-atrial natriuretic peptide (MR-proANP) predicts short- and long-term outcomes in respiratory tract infections: a prospective validation study. Vazquez M; Jockers K; Christ-Crain M; Zimmerli W; Müller B; Schuetz P Int J Cardiol; 2012 Apr; 156(1):16-23. PubMed ID: 21093937 [TBL] [Abstract][Full Text] [Related]
19. Vasoactive peptides with angiogenesis-regulating activity predict cancer risk in males. Belting M; Almgren P; Manjer J; Hedblad B; Struck J; Wang TJ; Bergmann A; Melander O Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):513-22. PubMed ID: 22267286 [TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]